New hope for tough Crohn's cases: drug trial targets scarred intestines
NCT ID NCT07177118
Summary
This study is testing two biologic drugs, risankizumab and ustekinumab, for people with a severe form of Crohn's disease where the intestines develop scar tissue and narrow. It's for patients whose current treatments have stopped working. The goal is to see if these drugs can prevent the scarring from getting worse and reduce painful blockages.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.